AstraZeneca, Abbisko partner on lung cancer combination therapy trial
Seeking Alpha ·
Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca ( AZN ) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer, the companies said on Wednesday. As a multicenter, open-label Phase I/II clinical study, the
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
254 participants
Related News
- Euro Area PMI lifts above estimates
- Germany's June services PMI tops forecasts
- Why Universal Technical Institute Stock Crushed it This Week
- France composite PMI misses market estimates
- Microsoft launches Microsoft Frontier Company with $2.5bn investment
- Walmart and Amazon remain at the top of US retail in 2026 rankings